Logo image of AVR

ANTERIS TECHNOLOGIES GLOBAL (AVR) Stock Fundamental Analysis

NASDAQ:AVR - Nasdaq - US03675P1021 - Common Stock - Currency: USD

3.25  -0.03 (-0.91%)

After market: 3.25 0 (0%)

Fundamental Rating

2

Overall AVR gets a fundamental rating of 2 out of 10. We evaluated AVR against 187 industry peers in the Health Care Equipment & Supplies industry. AVR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AVR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AVR had negative earnings in the past year.
AVR Yearly Net Income VS EBIT VS OCF VS FCFAVR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

AVR has a worse Return On Assets (-129.76%) than 86.10% of its industry peers.
With a Return On Equity value of -176.36%, AVR is not doing good in the industry: 70.59% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -129.76%
ROE -176.36%
ROIC N/A
ROA(3y)-145.5%
ROA(5y)N/A
ROE(3y)-232.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVR Yearly ROA, ROE, ROICAVR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -100 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 46.84%, AVR is in line with its industry, outperforming 40.64% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for AVR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.84%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVR Yearly Profit, Operating, Gross MarginsAVR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

4

2. Health

2.1 Basic Checks

AVR does not have a ROIC to compare to the WACC, probably because it is not profitable.
AVR has about the same amout of shares outstanding than it did 1 year ago.
The debt/assets ratio for AVR has been reduced compared to a year ago.
AVR Yearly Shares OutstandingAVR Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
AVR Yearly Total Debt VS Total AssetsAVR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -6.10, we must say that AVR is in the distress zone and has some risk of bankruptcy.
AVR has a Altman-Z score of -6.10. This is in the lower half of the industry: AVR underperforms 73.26% of its industry peers.
AVR has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
AVR has a Debt to Equity ratio of 0.00. This is in the better half of the industry: AVR outperforms 70.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.1
ROIC/WACCN/A
WACC9.02%
AVR Yearly LT Debt VS Equity VS FCFAVR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

A Current Ratio of 3.67 indicates that AVR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.67, AVR is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
AVR has a Quick Ratio of 3.65. This indicates that AVR is financially healthy and has no problem in meeting its short term obligations.
AVR has a Quick ratio of 3.65. This is in the better half of the industry: AVR outperforms 69.52% of its industry peers.
Industry RankSector Rank
Current Ratio 3.67
Quick Ratio 3.65
AVR Yearly Current Assets VS Current LiabilitesAVR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for AVR have decreased strongly by -65.77% in the last year.
Looking at the last year, AVR shows a decrease in Revenue. The Revenue has decreased by -1.16% in the last year.
EPS 1Y (TTM)-65.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-1.16%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AVR will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.58% on average per year.
AVR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 46.34% yearly.
EPS Next Y26.6%
EPS Next 2Y15.52%
EPS Next 3Y12.58%
EPS Next 5YN/A
Revenue Next Year21.94%
Revenue Next 2Y89.47%
Revenue Next 3Y46.34%
Revenue Next 5YN/A

3.3 Evolution

AVR Yearly Revenue VS EstimatesAVR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
AVR Yearly EPS VS EstimatesAVR Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AVR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVR Price Earnings VS Forward Price EarningsAVR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVR Per share dataAVR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

AVR's earnings are expected to grow with 12.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.52%
EPS Next 3Y12.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AVR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANTERIS TECHNOLOGIES GLOBAL

NASDAQ:AVR (7/25/2025, 8:00:01 PM)

After market: 3.25 0 (0%)

3.25

-0.03 (-0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)09-15 2025-09-15
Inst Owners57.35%
Inst Owner Change0%
Ins Owners4.13%
Ins Owner Change0%
Market Cap117.19M
Analysts80
Price Target16.83 (417.85%)
Short Float %2.83%
Short Ratio4.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-4.83%
Min Revenue beat(2)-27.62%
Max Revenue beat(2)17.96%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-7.74%
EPS NQ rev (3m)-14.28%
EPS NY rev (1m)-7.44%
EPS NY rev (3m)-13.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.14%
Revenue NY rev (1m)5.94%
Revenue NY rev (3m)2.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 43.36
P/FCF N/A
P/OCF N/A
P/B 2.71
P/tB 2.72
EV/EBITDA N/A
EPS(TTM)-2.12
EYN/A
EPS(NY)-1.96
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.07
BVpS1.2
TBVpS1.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -129.76%
ROE -176.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.84%
FCFM N/A
ROA(3y)-145.5%
ROA(5y)N/A
ROE(3y)-232.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.67
Quick Ratio 3.65
Altman-Z -6.1
F-ScoreN/A
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)191.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)74.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-65.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y26.6%
EPS Next 2Y15.52%
EPS Next 3Y12.58%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.16%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year21.94%
Revenue Next 2Y89.47%
Revenue Next 3Y46.34%
Revenue Next 5YN/A
EBIT growth 1Y-64.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.01%
EBIT Next 3Y6.05%
EBIT Next 5YN/A
FCF growth 1Y-71.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-76.84%
OCF growth 3YN/A
OCF growth 5YN/A